The company announced that it will cease development of Mosnodenvir, a drug candidate designed to be the first anti-viral treatment for dengue. It is unclear if another developer will license the ...

Progression to the phase 2b cohort follows recommendation of the Safety Review Committee (SRC) after it reviewed positive ...

The main treatment is supportive and symptomatic treatment by fluid-replacement therapy. Discovery of a new antiviral drug for dengue is the best hope for treatment.

Island Pharmaceuticals Ltd (ASX:ILA) has successfully enrolled its first subjects for a Phase 2b clinical trial to test the ...

Stockhead’s Fraser Palamara sits down with Island Pharmaceuticals (ASX:ILA)  CEO and managing director David Foster to get the short end of the long story on the company’s latest news.

The dengue outbreak in Bangladesh remains a significant public health challenge, with recent data revealing 67 ...

Surveillance and testing improvements in Tamil Nadu led to a rise in reported dengue cases, but fewer deaths in 2024.

Some diseases that have spread over the last few decades are untreatable with medicines. Recovery banks heavily on immunity & ...

Dual-listed regenerative medicine company Avita Medical has seen its share price slide ~19% today on a downgrade of its ...